Last update 01 Nov 2024
5-HT1D receptor x 5-HT1A receptor x MTNR1A x MTNR1B
Last update 01 Nov 2024
Basic Info
Related Targets |
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
An open-label sleep laboratory study of efficacy and safety of piromelatine in a well-defined population of patients with idiopathic (isolated) Rapid Eye Movement Behavior Disorder (iRBD). - Piromelatine PSG-RBD
Randomized, Delayed Start, Double Blind, Parallel Group, Placebo Controlled, Multicenter Study of Piromelatine 20 mg in Participants With Mild Dementia Due to Alzheimer's Disease
A randomized, double-blind, placebo-controlled, study of oral treatment of piromelatine in patients with ocular hypertension (OHT) or primary open angle glaucoma (POAG).
100 Clinical Results associated with 5-HT1D receptor x 5-HT1A receptor x MTNR1A x MTNR1B
Login to view more data
100 Translational Medicine associated with 5-HT1D receptor x 5-HT1A receptor x MTNR1A x MTNR1B
Login to view more data
Login to view more data
Analysis
Perform a panoramic analysis of this field.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free